Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis

Bibliography

• Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:269-81
   PubMed Web of Science ®Google Scholar
• Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow-up study of a primary care based inception cohort. Arthritis Rheum 2005;52:2293-9
   PubMed Web of Science ®Google Scholar
• Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46(8):2010-19
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A, et al. Effect of treatment strategy of tight control for rheumatoid arthritis (TICORA): a single blind, randomised control trial. Lancet 2004;364:263-9
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79
   PubMed Web of Science ®Google Scholar
• Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov 2006;5:185-6
   PubMed Web of Science ®Google Scholar
• Kremer JM. Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis. J Clin Rheumatol 2005;11(5):S55-S62
   PubMed Web of Science ®Google Scholar
• Stuart RW, Racke MK. Targeting T-cell co-stimulation in auto-immune disease Expert Opin Ther Targets 2002;6:275-89
   PubMedGoogle Scholar
• Fox DA. The role of T-cells in the immunopathogenesis of RA: new perspectives. Arhtitis Rheum 1997;40:598-609
   PubMed Web of Science ®Google Scholar
• Van Boxel JA, Paget SA. Predominantly T-cell inflitrate in rheumatoid synovial membranes. N Engl J Med 1975;293(11):517-20
   PubMed Web of Science ®Google Scholar
• Klimiuk PA, et al. Production of cytokines and metalloproteinases in rheumatoid arthritis is T-lymphocyte dependant. Clin Immunol 1999;90:65-78
   PubMed Web of Science ®Google Scholar
• Liu MF, Kohsaka H, Sakurai H, et al. The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium. Arthritis Rheum 1996;39(1):110-14
   PubMed Web of Science ®Google Scholar
• MacDonald KP, Nishioka Y, Lipsky PE, Thomas R. Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin Invest 1997;100(9):2404-14
   PubMed Web of Science ®Google Scholar
• Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-48
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Abbas KA. T-cell costimulation. Biology, Theraputic potential and Challenges. N Engl J Med 2006;355(10):973-5
   PubMed Web of Science ®Google Scholar
• Popa C, Leandro MJ, Cambridge G, Edwards JCW. Repeated B-lymphocyte depletion with rituximab in rheumatoid arthritis in 7 years. Rheumatology 2007;46(4):626-31
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Klareskog L, Singh A, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the Tempo Trial. Ann Rheum Dis 2006;65(3):328
   PubMed Web of Science ®Google Scholar
• Maddison P, Keily P, Kirkham B, et al. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology 2005;44(3):280-6
   PubMed Web of Science ®Google Scholar
• Reiser H, Stadeker MJ. Co-stimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996;335:1369-77
   PubMed Web of Science ®Google Scholar
• Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle MK, Ledbetter JA. CTLA-4 is a second receptor for the B-cell activation antigen B7. J Exp Med 1991;174:561-9
   PubMed Web of Science ®Google Scholar
• Linsley PS, et al. Immunosuppresion in vivo by a soluble form of CTLA4 T-cell activation molecule. Science 1992;257:729-95
   Web of Science ®Google Scholar
• FDA labelling information. Available at: URL:www.fda.gov/oder/foi/label/2005/1251181bl.pdf> (2005)
   Google Scholar
• Boyce EG. Abatacept: the first co-stimulation modulator for use in RA. Formulary 2006;41(7):322-6
   Web of Science ®Google Scholar
• Moreland LW, Alten R, Van den Bosch F, et al. Co-stimulatory blockade in patients with rheumatoid arthritis: a pilot, dose finding, double blind, placebo controlled clinical trialevaluating CTLA-4 Ig and LEA 29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-9
   PubMed Web of Science ®Google Scholar
• Kremer JM, Westhovens R, Leon M, et al. treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA-4 Ig. N Engl J Med 2003;349:1907-15
   PubMed Web of Science ®Google Scholar
• Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a Phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52(8):2263-71
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Schiff M, Goldman A, Kremer J. Selective co stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007;66(2):228
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genent HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a Randomized Trial. Ann Intern Med 2006;144(12):865-76
   PubMed Web of Science ®Google Scholar
• Enovese MC, et al. Abatacept for rheumatoid arthritis refractory to TNF-alpha inhibition. New Engl Med J 2005;353:1114-23
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54(9):2807-16
   PubMed Web of Science ®Google Scholar
• Golimumab (CNTO 148) shows clinical benefit in active rheumatoid arthritis. American College of Rheumatology Annual Scientific Meeting; 2005
   Google Scholar
• Chugai Pharmaceutical company Ltd. Tocilizumab monotherapy reported to slow joint damage in patients with RA. Data presented at ACR, San Diego; 2006
   Google Scholar
• EMEA/144134/2007; London March 2007
   Google Scholar
• EMEA/CHMP/72407/2007; London, March 2007
   Google Scholar
• Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with Abatacept, who have inadequate response to anti-TNF therapy in a double blind, placebo controlled, multicentre randomised clinical trial. Rheumatology 2006;45:1238-46
   PubMed Web of Science ®Google Scholar
• Emery P, Kosinsky M, Li T, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumol 2006;33(4):681-9
   PubMed Web of Science ®Google Scholar
• Weisman M, Durez P, Hallegua D, Nuamah I, Vratsanos G, Becker JC. Abatacept inhibits T-cell activation and the subsequent activation of inflammatory cell types, as demonstrated by sustained reductions in multiple inflammatory biomarkers. Ann Rheum Dis 2004;63(Suppl 1):i138 (Abstract)
   PubMed Web of Science ®Google Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16
   PubMed Web of Science ®Google Scholar